Cited by 243Cancer, Hypoxia, and MetabolismBiochemical Acid Research StudiesGlioma Diagnosis and Treatment

The DOI matches its Crossref record; 136 of the 138 references it cites were found in a registry or an index.

Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates

Open access

Ye, Dan, Guan, Kun-Liang, Xiong, Yue·2018·Trends in Cancer

DOI 10.1016/j.trecan.2017.12.005PMC PMC5884165

Open this paper in CoChat — free account Open PDF

Abstract

Isocitrate dehydrogenases (IDH1/2) are frequently mutated in multiple types of human cancer, resulting in neomorphic enzymes that convert α-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG). The current view on the mechanism of IDH mutation holds that 2-HG acts as an antagonist of α-KG to competitively inhibit the activity of α-KG-dependent dioxygenases, including those involved in histone and DNA demethylation. Recent studies have implicated 2-HG in activities beyond epigenetic modification. Multiple enzymes have been discovered that lack mutations but that can nevertheless produce 2-HG promiscuously under hypoxic or acidic conditions. Therapies are being developed to treat IDH-mutant cancers by targeting either the mutant IDH enzymes directly or the pathways sensitized by 2-HG.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.trecan.2017.12.005

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Figure 1 Metabolism and Targets of 2-Hydroxyglutarate (2-HG) The thick and thin arrows represent the primary and promiscuous reactions, respectively. FAD, flavin adenine dinucleotide; FADH2, reduced form of FAD; NADP, nicotinamide adenine dinucleotide phosphate; NADPH, reduced form of NADP. Additional abbreviations are listed in Table 1.CC BY-NC-ND · PubMed Central

Figure 2 Production of 2-Hydroxyglutarate (2-HG) by Promiscuous Enzymatic Reactions The thick and thin arrows represent the primary and promiscuous reactions, respectively. PHDGH, phosphoglycerate dehydrogenase; 3PG, 3-phosphoglycerate; 3PHP, 3-phosphohydroxypyruvate. Additional abbreviations are listed in Figure 1.CC BY-NC-ND · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251 · cited 1×
“EGLN/PHD-mediated regulation of HIF-1α is the core of ancient oxygen-monitoring machinery used by metazoans from the nematode Caenorhabditis elegans to humans [129].”
Background
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Self-citation
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219

Show all 138 references

Sorted by citations

Cancer metabolism: looking forward
Martínez‐Reyes, I., & Chandel, N. S. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00378-6 · Cited by 1,877
Metabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2021) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 818
The language of chromatin modification in human cancers
Zhao, S., Allis, C. D., & Wang, G. G. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00357-x · Cited by 420
Coupling Krebs cycle metabolites to signalling in immunity and cancer
Ryan, D. G., Murphy, M. P., Frezza, C., Prag, H. A., Chouchani, E. T., O’Neill, L. A., & Mills, E. L. (2018) · Nature Metabolism · doi:10.1038/s42255-018-0014-7 · Cited by 398
Metabolic signatures of cancer cells and stem cells
Intlekofer, A. M., & Finley, L. W. S. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0032-0 · Cited by 322
Detection and analysis of chiral molecules as disease biomarkers
Liu, Y., Wu, Z., Armstrong, D. W., Wolosker, H., & Zheng, Y. (2023) · Nature Reviews Chemistry · doi:10.1038/s41570-023-00476-z · Cited by 261
Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting
Sullivan, M. R., Mattaini, K. R., Dennstedt, E. A., Nguyen, A. A., Sivanand, S., Reilly, M. F., Meeth, K. M., Muir, A., Darnell, A. M., Bosenberg, M., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.015 · Cited by 250
Itaconate inhibits TET DNA dioxygenases to dampen inflammatory responses
Chen, L., Morcelle, C., Cheng, Z., Chen, X., Xu, Y., Gao, Y., Song, J., Li, Z., Smith, M. D., Shi, M., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00853-8 · Cited by 234
Self-citation
The Mitochondrion as an Emerging Therapeutic Target in Cancer
Roth, K. G., Mambetsariev, I., Kulkarni, P., & Salgia, R. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.06.009 · Cited by 219
Metabolic Signaling to the Nucleus in Cancer
Campbell, S. L., & Wellen, K. E. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.015 · Cited by 186
Sex Differences in Intestinal Carbohydrate Metabolism Promote Food Intake and Sperm Maturation
Hudry, B., de Goeij, E., Mineo, A., Gaspar, P., Hadjieconomou, D., Studd, C., Mokochinski, J. B., Kramer, H., Plaçais, P.-Y., Préat, T., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.029 · Cited by 164
Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease
Tommasini-Ghelfi, S., Murnan, K., Kouri, F. M., Mahajan, A., May, J., & Stegh, A. H. (2019) · Science Advances · doi:10.1126/sciadv.aaw4543 · Cited by 166
HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells
Lee, S.-H., Golinska, M., & Griffiths, J. R. (2021) · Cells · doi:10.3390/cells10092371 · Cited by 169
Current and emerging therapies for advanced biliary tract cancers
Kam, A. E., Masood, A., & Shroff, R. T. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00171-0 · Cited by 170
Metabolic remodelling during early mouse embryo development
Zhao, J., Yao, K., Yu, H., Zhang, L., Xu, Y., Chen, L., Sun, Z., Zhu, Y., Zhang, C., Qian, Y., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00464-x · Cited by 167
Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma
Wu, M., Shi, L., Dubrot, J., Merritt, J., Vijay, V., Wei, T.-Y., Kessler, E., Olander, K. E., Adil, R., Pankaj, A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1077 · Cited by 158
The Roles of 2-Hydroxyglutarate
Du, X., & Hu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.651317 · Cited by 160
TET Enzymes and 5hmC in Adaptive and Innate Immune Systems
Lio, C. J., & Rao, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00210 · Cited by 144
Cancer metabolism and tumor microenvironment: fostering each other?
Yuan, Y., Li, H., Wang, P., Chen, L., Guo, D. S., Jiang, H., He, B., Qin, S., Wang, K., Li, N., et al. (2021) · Science China Life Sciences · doi:10.1007/s11427-021-1999-2 · Cited by 140
Self-citation
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
Stuani, L., Sabatier, M., Wang, F., Poupin, N., Bosc, C., Saland, E., Castelli, F. A., Gales, L., Montersino, C., Boët, E., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20200924 · Cited by 143
Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH
Tan, M., Mosaoa, R., Graham, G. T., Kasprzyk-Pawelec, A., Gadre, S. M., Parasido, E., Catalina-Rodriguez, O., Foley, P. L., Giaccone, G., Cheema, A. K., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0491-6 · Cited by 130
2-Hydroxyglutarate in Cancer Cells
Ježek, P. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7902 · Cited by 130
Reprogramming of serine, glycine and one-carbon metabolism in cancer
Li, A. M., & Ye, J. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165841 · Cited by 127
Microenvironmental regulation of cancer cell metabolism: implications for experimental design and translational studies
Muir, A., Danai, L. V., & Heiden, M. G. V. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.035758 · Cited by 124
Two genomes, one cell: Mitochondrial-nuclear coordination via epigenetic pathways
Wiese, M., & Bannister, A. J. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.01.006 · Cited by 122
Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins
Kaminska, B., Czapski, B., Guzik, R., Król, S. K., & Gielniewski, B. (2019) · Molecules · doi:10.3390/molecules24050968 · Cited by 113
Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities
Oh, S., Yeom, J., Cho, H. J., Kim, J.-H., Yoon, S., Kim, H.-D., Sa, J. K., Ju, S., Lee, H., Oh, M. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17139-y · Cited by 100
Widespread bacterial lysine degradation proceeding via glutarate and L-2-hydroxyglutarate
Knorr, S., Sinn, M., Galetskiy, D., Williams, R. M., Wang, C., Müller, N., Mayans, O. M., Schleheck, D., & Hartig, J. S. (2018) · Nature Communications · doi:10.1038/s41467-018-07563-6 · Cited by 97
The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis
Wang, T., Liang, J.-Y., Zhang, C., Xiong, Y., Guan, K., & Yuan, H. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1984-4 · Cited by 106
Self-citation
An LKB1–mitochondria axis controls TH17 effector function
Baixauli, F., Piletič, K., Puleston, D. J., Villa, M., Field, C. S., Flachsmann, L. J., Quintana, A., Rana, N., Edwards-Hicks, J., Matsushita, M., et al. (2022) · Nature · doi:10.1038/s41586-022-05264-1 · Cited by 102
Defining a metabolic landscape of tumours: genome meets metabolism
Nanda, C. S., Venkateswaran, S. V., Patani, N., & Yuneva, M. O. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0663-7 · Cited by 95
Mitochondrial and metabolic alterations in cancer cells
Gregorio, J. D., Petricca, S., Iorio, R., Toniato, E., & Flati, V. (2022) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2022.151225 · Cited by 97
The Role of D-3-Phosphoglycerate Dehydrogenase in Cancer
Zhao, X., Fu, J., Du, J., & Xu, W. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.41051 · Cited by 93
Role of Metabolism in Bone Development and Homeostasis
Suzuki, A., Minamide, M., Iwaya, C., Ogata, K., & Iwata, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238992 · Cited by 92
Recent advances of IDH1 mutant inhibitor in cancer therapy
Tian, W., Zhang, W., Wang, Y., Jin, R., Wang, Y., Guo, H., Tang, Y., & Yao, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.982424 · Cited by 88
Anion-exchange chromatography mass spectrometry provides extensive coverage of primary metabolic pathways revealing altered metabolism in IDH1 mutant cells
Walsby-Tickle, J., Gannon, J. M., Hvinden, I. C., Bardella, C., Abboud, M. I., Nazeer, A., Hauton, D., Pires, E., Cadoux-Hudson, T. A. D., Schofield, C. J., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0957-6 · Cited by 78
Aging: All roads lead to mitochondria
Son, J. M., & Lee, C. D. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.02.006 · Cited by 86
The Mitochondrial Citrate Carrier SLC25A1/CIC and the Fundamental Role of Citrate in Cancer, Inflammation and Beyond
Mosaoa, R., Kasprzyk-Pawelec, A., Fernandez, H. R., & Avantaggiati, M. L. (2021) · Biomolecules · doi:10.3390/biom11020141 · Cited by 80
The Tricarboxylic Acid Cycle at the Crossroad Between Cancer and Immunity
Scagliola, A., Mainini, F., & Cardaci, S. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7974 · Cited by 75
Metabolites are not genes — avoiding the misuse of pathway analysis in metabolomics
Lee, K. S., Su, X., & Huan, T. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01283-0 · Cited by 75
Itaconate in host inflammation and defense
Ye, D., Wang, P., Chen, L., Guan, K., & Xiong, Y. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.02.004 · Cited by 72
Self-citation
Astrocytoma: A Hormone-Sensitive Tumor?
Hirtz, A., Rech, F., Dubois‐Pot‐Schneider, H., & Dumond, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239114 · Cited by 69
IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
Cerchione, C., Romano, A., Daver, N. G., Dinardo, C. D., Jabbour, E. J., Konopleva, M. Y., Ravandi‐Kashani, F., Kadia, T. M., Martelli, M. P., Isidori, A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.639387 · Cited by 73
Differentiating enantiomers by directional rotation of ions in a mass spectrometer
Zhou, X., Wang, Z., Li, S., Rong, X., Bu, J., Liu, Q., & Ouyang, Z. (2024) · Science · doi:10.1126/science.adj8342 · Cited by 68
Cellular Compartmentation and the Redox/Nonredox Functions of NAD +
Kulkarni, C. A., & Brookes, P. S. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2018.7722 · Cited by 68
Dual mechanisms of posttranscriptional regulation of Tet2 by Let-7 microRNA in macrophages
Jiang, S., Yan, W., Wang, S. E., & Baltimore, D. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811040116 · Cited by 63
Metabolic Rewiring in Glioblastoma Cancer: EGFR, IDH and Beyond
Khayari, A. E., Bouchmaa, N., Taïb, B., Wei, Z., Zeng, A., & Fatimy, R. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.901951 · Cited by 65
Oncometabolites as biomarkers in thyroid cancer: a systematic review
Khatami, F., Payab, M., Sarvari, M., Gilany, K., Larijani, B. A., Arjmand, B., & Tavangar, S. M. (2019) · Cancer Management and Research · doi:10.2147/cmar.s188661 · Cited by 59
Therapeutic Targeting of Cancer Stem Cells: Integrating and Exploiting the Acidic Niche
Linden, C. V., & Corbet, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00159 · Cited by 58
Glutamine metabolism in Th17/Treg cell fate: applications in Th17 cell-associated diseases
Yang, G., Xia, Y., & Ren, W. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1703-2 · Cited by 55
Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
Hvinden, I. C., Cadoux-Hudson, T. A. D., Schofield, C. J., & McCullagh, J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100469 · Cited by 63
Signaling metabolite L-2-hydroxyglutarate activates the transcription factor HIF-1α in lipopolysaccharide-activated macrophages
Williams, N. C., Ryan, D. G., Costa, A. S. H., Mills, E. L., Jedrychowski, M. P., Cloonan, S. M., Frezza, C., & O'Neill, L. A. J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101501 · Cited by 57
Metabolic regulation in the immune response to cancer
Wu, Q., Yu, X., Li, J., Sun, S., & Tu, Y. (2021) · 癌症：英文版 · doi:10.1002/cac2.12182 · Cited by 57
Endogenous toxic metabolites and implications in cancer therapy
Lee, N., Spears, M. E., Carlisle, A. E., & Kim, D. (2020) · Oncogene · doi:10.1038/s41388-020-01395-9 · Cited by 56
Wild-Type IDH Enzymes as Actionable Targets for Cancer Therapy
Bergaggio, E., & Piva, R. (2019) · Cancers · doi:10.3390/cancers11040563 · Cited by 52
Mitochondrial hydrogen peroxide production by pyruvate dehydrogenase and α-ketoglutarate dehydrogenase in oxidative eustress and oxidative distress
Chalifoux, O., Faerman, B., & Mailloux, R. J. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105399 · Cited by 51
Bodywide ecological interventions on cancer
Kroemer, G., McQuade, J. L., Mérad, M., André, F., & Zitvogel, L. (2023) · Nature Medicine · doi:10.1038/s41591-022-02193-4 · Cited by 51
Oncometabolites in cancer aggressiveness and tumour repopulation
Dando, I., Pozza, E. D., Ambrosini, G., Torrens‐Mas, M., Butera, G., Mullappilly, N., Pacchiana, R., Palmieri, M., & Donadelli, M. (2019) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12513 · Cited by 49
Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapies
Wang, R., Zhuang, J., Zhang, Q., Wu, W., Yu, X., Zhang, H., & Xie, Z. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00689-6 · Cited by 52
ALKBH5 modulates hematopoietic stem and progenitor cell energy metabolism through m6A modification-mediated RNA stability control
Gao, Y., Zimmer, J. T., Vasic, R., Liu, C., Gbyli, R., Zheng, S.-J., Patel, A. J., Liu, W., Qi, Z., Li, Y., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113163 · Cited by 46
Metabolite regulation of epigenetics in cancer
Wang, P., Chen, L., Xiong, Y., & Ye, D. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114815 · Cited by 50
Self-citation
The metabolic reprogramming in acute myeloid leukemia patients depends on their genotype and is a prognostic marker
Presti, C. L., Fauvelle, F., Jacob, M., Mondet, J., & Mossuz, P. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002981 · Cited by 45
PSPH promotes melanoma growth and metastasis by metabolic deregulation-mediated transcriptional activation of NR4A1
Rawat, V., Malvi, P., Della Manna, D., Yang, E. S., Bugide, S., Zhang, X., Gupta, R., & Wajapeyee, N. (2021) · Oncogene · doi:10.1038/s41388-021-01683-y · Cited by 43
Regulation of Metabolic Homeostasis in Cell Culture Bioprocesses
O’Brien, C. M., Mulukutla, B. C., Mashek, D. G., & Hu, W. (2020) · Trends in biotechnology · doi:10.1016/j.tibtech.2020.02.005 · Cited by 43
d-2-Hydroxyglutarate is an anti-inflammatory immunometabolite that accumulates in macrophages after TLR4 activation
de Goede, K. E., Harber, K. J., Gorki, F. S., Verberk, S. G. S., Groh, L. A., Keuning, E. D., Struys, E. A., van Weeghel, M., Haschemi, A., de Winther, M. P. J., et al. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166427 · Cited by 43
IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas
Fujita, Y., Nunez-Rubiano, L., Dono, A., Bellman, A., Shah, M., Rodrı́guez, J. C., Putluri, V., Kamal, A. H. M., Putluri, N., Riascos, R., et al. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-04060-1 · Cited by 39
Human 2-oxoglutarate-dependent oxygenases: nutrient sensors, stress responders, and disease mediators
Fletcher, S. C., & Coleman, M. L. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190333 · Cited by 44
Mitochondrial DNA Alterations in Glioblastoma (GBM)
Barros, M. B. L., Pinheiro, D. D. R., & Borges, B. D. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115855 · Cited by 42
Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2
Liu, Y., Chou, F.-J., Lang, F., Zhang, M., Song, H., Zhang, W., Davis, D. L., Briceno, N., Zhang, Y., Cimino, P. J., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3179 · Cited by 43
Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease
Baliga, M. M., Klawitter, J., Christians, U., Hopp, K., Chonchol, M., Gitomer, B. Y., Cadnapaphornchai, M. A., & Klawitter, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-84609-8 · Cited by 41
Metabolic adaptation of NK cell activity and behavior in tumors: challenges and therapeutic opportunities
Borde, S., & Matosevic, S. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.08.009 · Cited by 41
Whole-genome analysis of TET dioxygenase function in regulatory T cells
Yue, X., Samaniego‐Castruita, D., González‐Avalos, E., Li, X., Barwick, B. G., & Rao, A. (2021) · EMBO Reports · doi:10.15252/embr.202152716 · Cited by 37
An l-2-hydroxyglutarate biosensor based on specific transcriptional regulator LhgR
Kang, Z., Zhang, M., Gao, K., Zhang, W., Meng, W., Liu, Y., Xiao, D., Guo, S., Ma, C., Gao, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23723-7 · Cited by 41
Primary Metabolite Responses to Oxidative Stress in Early-Senescing and Paraquat Resistant Arabidopsis thaliana rcd1 (Radical-Induced Cell Death1)
Sipari, N., Lihavainen, J., Shapiguzov, A., Kangasjärvi, J., & Keinänen, M. (2020) · Frontiers in Plant Science · doi:10.3389/fpls.2020.00194 · Cited by 38
The transcription factors aryl hydrocarbon receptor and MYC cooperate in the regulation of cellular metabolism
Lafita‐Navarro, M. C., Perez‐Castro, L., Zacharias, L. G., Barnes, S. D., DeBerardinis, R. J., & Conacci‐Sorrell, M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ac120.014189 · Cited by 37
Magnetic resonance spectroscopy for the study of cns malignancies
Ruiz‐Rodado, V., Brender, J., Cherukuri, M. K., Gilbert, M. R., & Larion, M. (2020) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2020.11.001 · Cited by 37
A d-2-hydroxyglutarate biosensor based on specific transcriptional regulator DhdR
Xiao, D., Zhang, W., Guo, X., Liu, Y., Hu, C., Guo, S., Kang, Z., Xu, X., Ma, C., Gao, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27357-7 · Cited by 34
Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations
Buege, M. J., DiPippo, A. J., & Dinardo, C. D. (2018) · Cancers · doi:10.3390/cancers10060187 · Cited by 35
Molecular Mediators of Metabolic Reprogramming in Cancer: Mechanisms, Regulatory Networks, and Therapeutic Strategies
Ahuja, S., & Zaheer, S. (2025) · Immunology · doi:10.1111/imm.70045 · Cited by 43
Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective
Ma, T., Zou, F., Pusch, S., Xu, Y., von Deimling, A., & Zha, X. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00159 · Cited by 35
Harnessing Lactate Metabolism for Radiosensitization
Liu, K. X., Everdell, E., Pal, S., Haas-Kogan, D. A., & Milligan, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672339 · Cited by 36
A comprehensive review on signaling attributes of serine and serine metabolism in health and disease
Wu, D., Zhang, K., Khan, F. A., Pandupuspitasari, N. S., Guan, K., Sun, F., & Huang, C. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129607 · Cited by 35
Self-citation
Structure, substrate specificity, and catalytic mechanism of human D-2-HGDH and insights into pathogenicity of disease-associated mutations
Yang, J., Zhu, H., Zhang, T., & Ding, J. (2021) · Cell Discovery · doi:10.1038/s41421-020-00227-0 · Cited by 32
Regulation of tumor metabolism by post translational modifications on metabolic enzymes
Dessai, A. S., Kalhotra, P., Novickis, A. T., & Dasgupta, S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00521-x · Cited by 38
Deciphering the Warburg Effect: Metabolic Reprogramming, Epigenetic Remodeling, and Cell Dedifferentiation
Li, A. M., & Ye, J. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062822-120857 · Cited by 31
Rapid diagnosis of IDH1-mutated gliomas by 2-HG detection with gas chromatography mass spectrometry
Xu, H., Xia, Y., Li, C., Zhang, J., Liu, Y., Wei, Y., Qin, Z., Chen, L., Shi, Z., Quan, K., et al. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0163-z · Cited by 32
Self-citation
Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions
Lavacchi, D., Caliman, E., Rossi, G., Buttitta, E., Botteri, C., Fancelli, S., Pellegrini, E., Roviello, G., Pillozzi, S., & Antonuzzo, L. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108170 · Cited by 32
Isocitrate dehydrogenase 3b is required for spermiogenesis but dispensable for retinal viability
Zhu, S., Huang, J., Xu, R., Wang, Y., Wan, Y., McNeel, R., Parker, E. D., Kolson, D. R., Yam, M., Webb, B. A., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102387 · Cited by 35
IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future Perspectives
Crispo, F., Pietrafesa, M., Condelli, V., Maddalena, F., Bruno, G., Piscazzi, A., Sgambato, A., Esposito, F., & Landriscina, M. (2020) · Molecules · doi:10.3390/molecules25163754 · Cited by 32
Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives
Carosi, F., Broseghini, E., Fabbri, L., Corradi, G., Gili, R., Forte, V., Roncarati, R., Filippini, D. M., & Ferracin, M. (2024) · Cancers · doi:10.3390/cancers16152752 · Cited by 31
MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome
Qiu, Z., Lin, A., Jiang, S., Elkashef, S. M., Myers, J., Srikantan, S., Sasi, B. K., Cao, J. Z., Godley, L. A., Rakheja, D., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.02.002 · Cited by 31
Optimized Protocol for the In Situ Derivatization of Glutathione with N-Ethylmaleimide in Cultured Cells and the Simultaneous Determination of Glutathione/Glutathione Disulfide Ratio by HPLC-UV-QTOF-MS
Sun, X., Berger, R. S., Heinrich, P., Marchiq, I., Pouysségur, J., Renner, K., Oefner, P. J., & Dettmer, K. (2020) · Metabolites · doi:10.3390/metabo10070292 · Cited by 29
Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation
Fan, B., Dai, D., Dinardo, C. D., Stein, E. M., de Botton, S., Attar, E. C., Liu, H., Liu, G., Lemieux, I. R., Agresta, S. V., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04064-6 · Cited by 28
Isocitrate dehydrogenase gene variants in cancer and their clinical significance
Cadoux-Hudson, T. A. D., Schofield, C. J., & McCullagh, J. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210277 · Cited by 28
5-methylcytosine turnover: Mechanisms and therapeutic implications in cancer
Turpin, M., & Salbert, G. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.976862 · Cited by 31
A Drosophila model of combined D-2- and L-2-hydroxyglutaric aciduria reveals a mechanism linking mitochondrial citrate export with oncometabolite accumulation
Li, H., Hurlburt, A. J., & Tennessen, J. M. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.035337 · Cited by 27
Metabolic Reprogramming of Mouse Bone Marrow Derived Macrophages Following Erythrophagocytosis
Catala, A., Youssef, L. A., Reisz, J. A., Dzieciątkowska, M., Powers, N. E., Marchetti, C., Karafin, M. S., Zimring, J. C., Hudson, K. E., Hansen, K. C., et al. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00396 · Cited by 28
MYC, mitochondrial metabolism and O-GlcNAcylation converge to modulate the activity and subcellular localization of DNA and RNA demethylases
Lin, A.-P., Qiu, Z., Ethiraj, P., Sasi, B., Jaafar, C., Rakheja, D., & Aguiar, R. C. T. (2022) · Leukemia · doi:10.1038/s41375-021-01489-7 · Cited by 25
2-Hydroxyglutarate destabilizes chromatin regulatory landscape and lineage fidelity to promote cellular heterogeneity
Kusi, M., Zand, M., Lin, L., Chen, M., Lopez, A., Lin, C.-L., Wang, C., Lucio, N. L. L., Kirma, N. B., Ruan, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110220 · Cited by 28
Metabolic challengers selecting tumor-persistent cells
Mancini, C., Lori, G., Pranzini, E., & Taddei, M. L. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.11.005 · Cited by 25

Authors: Ye, D., Guan, K.-L., & Xiong, Y.
Affiliations: Shanghai Medical College of Fudan University (CN)
University of North Carolina at Chapel Hill (US)
Corresponding author: Ye, Dan
Xiong, Yue
ORCID: Ye, Dan
Guan, Kun-Liang
Xiong, Yue
Venue: Trends in Cancer
Publisher: Elsevier BV
Published: 2018-02
Volume: 4
Issue: 2
Pages: 151-165
ISSN: 2405-8025 (ISSN-L)
2405-8033
DOI: 10.1016/j.trecan.2017.12.005
PMC: PMC5884165
OpenAlex: W2782192099
Cited by: 242
References: 138
Citations by year: 2026: 26 · 2025: 31 · 2024: 23 · 2023: 28 · 2022: 30 · 2021: 38 · 2020: 29 · 2019: 25 · 2018: 11
FWCI: 2.69
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Trends in cancer (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion, cc-by-nc-nd)
PubMed Central (acceptedVersion, cc-by-nc-nd)
eScholarship (California Digital Library) (submittedVersion)
eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
Funders: National Key R&D Program of China (2016YFA0501800)
NSFC (81522033, 81372198)
Shanghai Committee of Science and Technology (16JC1404000)
NIH (CA196878, GM51586, CA063834, CA163834)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Biochemical Acid Research Studies
Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Keywords: 2-hydroxyglutarate, IDH mutation, IDH1, IDH2, alpha-ketoglutarate, epigenetic demethylation, histone demethylation, DNA demethylation, hypoxia, acidosis
MeSH terms: Animals, Glutarates, Humans, Isocitrate Dehydrogenase, Mutation, Neoplasms, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks